Disruption of maternal IgA by prenatal antibiotics precedes intestinal *E. coli* colonization and late-onset sepsis in neonates

Katya McDonald[1], Danielle Browning[2], Kara G. Greenfield[1], Kathryn Lin[1], Josephine Meier[1], Matthew Butoryak[3], Alexandria Sasaki[4], Timothy Hand[3,5], Christina Megli[4,6], Kathryn A. Knoop[1,7*]

[1]Department of Immunology, Mayo Clinic, Rochester, MN, USA

[2]Division of Neonatology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

[3]Pediatrics Department, Infectious Disease Section, R.K. Mellon Institute for Pediatric Research, UPMC Children's Hospital of Pittsburgh, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[4]Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

[5]Department of Immunology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[6]Magee-Womens Research Institute, Pittsburgh, PA, USA

[7]Department of Pediatrics, Mayo Clinic, Rochester, MN, USA

[*]Send Correspondence to: Kathryn Knoop, Knoop.kathryn@mayo.edu

Abstract

Neonates, most notably prematurely born neonates, are particularly vulnerable to enteric pathogens. It is recommended that all pregnant patients receive antibiotics following Preterm Premature Rupture of Membranes (PPROM) to prolong pregnancy, yet not all antibiotic regimens have been studied for efficacy, especially when considering neonatal outcomes. Here we find, in a clinical cohort of at-risk infants, broad spectrum antibiotic treatment, including cephalosporins, increased the risk of LOS in neonates in comparison to penicillin base treatments. We followed those initial clinical findings with a preclinical model, here showing that prenatal cephalosporin antibiotics, but not penicillins, decreased mammary IgA in dams, and limited the availability of IgA within the lumen of nursing offspring. Decreased IgA correlated with an outgrowth of commensal *E.coli* and increased colonization and translocation of pathogen *E. coli.* This increased risk for mortality in a model of LOS that was associated with decreased mammary IgA. We propose maternal administration of select antibiotics could limit maternal IgA availability by disrupting mammary IgA, leading to increased risk of LOS in infants by allowing for pathogen colonization in the neonatal intestine.

34 **Introduction**

35 Late-onset neonatal sepsis (LOS) resulting from bloodstream infections occurring 7 days
36 following delivery, are a major contributor to neonatal mortality. Very low birth weight (VLBW,
37 <1500 grams) infants are particularly at risk for LOS, with an incidence of 10%, and a mortality
38 rate of 18% (*1*). In a substantial portion of LOS, the causative pathogen, including gram-positive
39 or gram-negative bacteria, in can be found residing in the neonatal intestine as part of the
40 intestinal microbial community implying intestinal translocation as the bacterial source (*2-6*) .
41 Accordingly, multiple animal models of LOS show gut-administered enteric pathogens can
42 breech the intestinal barrier and secondarily disseminate causing systemic disease (*7-9*). Thus,
43 the route of LOS is in stark contrast to early-onset sepsis, neonatal sepsis occurring >72 hours
44 following delivery, thought to be the result of a bacterial infection introduced *in utero* or during
45 the delivery process. Human studies have also demonstrated that enteral route of infection
46 contributes to morbidity and mortality (*10*) of LOS. *Escherichia coli* (*E. coli)* is the second most
47 common causative pathogen of LOS. Thus, there is a clear need to understand the causative risks
48 for LOS compared to early-onset sepsis. In a substantial portion of LOS-causative bloodstream
49 infections, *E.* coli has been demonstrated to reside in the neonatal gut microbial community prior
50 to disease (*11-14*). As *E. coli* is a common member of the neonatal intestinal microbiota, luminal
51 protection within the neonatal intestinal is key to preventing opportunistic pathogens from
52 disseminating systemically.

53 Maternal milk contains numerous factors that are protective against the development of LOS ,
54 including oligosaccharides, secretory antibodies, growth factors and lactoferrin that contributed
55 to protection against infection in the neonate (*15-17*). Overall, maternal milk has been linked
56 with lower infant death, hospitalization risk and risk of sepsis (*18-21*). Immunoglobulin A (IgA)
57 has long been known to be a valuable component of maternal milk in providing protection to the
58 neonate by binding pathogens (*22, 23*). Maternal IgA cross-reacts to a variety of gut resident
59 pathogens, including viruses, bacteria, and parasites (*24-26*), and shapes the developing neonatal
60 microbiome (*27-29*). Maternal IgA originates from plasma cells that migrate from the maternal
61 gastrointestinal tract (*30, 31*), delineating the "Gut-Mammary Axis" (*32*).

62 While neonatal antibiotic use has been shown to increase risk to LOS, perinatal maternal
63 antibiotics can also affect the neonate (*33, 34*). Antibiotics are prescribed in 25-30% of all

64 pregnancies, making them the most common medication given to pregnant women (*35*). Indeed,
65 in contemporary management of Preterm Premature Rupture of Membranes (PPROM), it is
66 recommended that all pregnant patients receive antibiotics to prolong pregnancy. Previous
67 studies have demonstrated that broader spectrum antibiotics were associated with increased LOS,
68 NEC and adverse neonatal outcomes in patients who present with PPROM (*36*). Despite this,
69 there are clinical trends towards use of additional broad-spectrum antibiotics without prospective
70 safety studies, culture guided treatments and without neonatal follow up. This is particularly
71 relevant when using salvage regimens for antimicrobial therapy in the setting of a penicillin
72 allergy. Recent observations in mice has shown maternal antibiotics throughout lactation can
73 decrease mammary IgA through influence of the gut microbiota (*31*). In this study, we sought to
74 determine if antenatal use of broader spectrum antimicrobials leads to increased susceptibility to
75 LOS and NEC in a high-risk cohort of premature infants who were exposed to maternal breast
76 milk. We found a strong association with alternate, broader spectrum maternal antibiotic use and
77 the development of LOS. Additionally, broad spectrum antibiotics lead to increased
78 susceptibility of LOS in mice that was secondary to significantly reduced maternal IgA passed to
79 the nursing neonate *with* decreased binding of *E. coli* in the nursing offspring. Thus, maternal
80 antibiotics may increase risk of LOS in infants through the reduction of pathogen-reactive IgA in
81 maternal milk.

82

83 **Results**

84 *Antenatal cephalosporin and non-beta lactam use is associated with increased rates of LOS.*

85 To determine if there was a clinical association of antenatal antibiotic exposure and adverse
86 neonatal outcomes, we generated a cohort of neonates born to mothers with PPROM (Fig. 1).
87 The recommended regimen following PPROM is ampicillin IV for 48 hours followed by
88 amoxicillin orally for 7 days in combination with a macrolide antibiotic (traditionally
89 erythromycin, and not azithromycin). The recommended antibiotics in the setting of a penicillin
90 allergy are unclear and left up to the clinician. We identified patients through ICD9/ICD10 codes
91 in the maternal chart and detailed maternal and neonatal chart review (Fig. 1). There was no
92 difference in pregnancy latency, gestational age at delivery, gestational age at PPROM, days that
93 patient received antibiotics for and breast milk feeding of neonates (Supplementary Table 1).

When assessing neonatal outcomes, there was no difference in select neonatal outcomes including early onset sepsis and NEC>2A. However, there was a significant increased risk of late onset sepsis with exposure to broader spectrum antibiotics with an OR of 4.836 ($p<0.0008$) (Table 1). A subanalysis demonstrated that 2 neonates who developed LOS in the traditional antibiotics cohort were fed donor breast milk, the remainder were fed with maternal breast milk that was fortified as needed. There was incomplete data for one neonate who was treated for LOS in the non-traditional cohort. In this context, a comparison was made between maternal breastmilk exposed infants in the traditional and nontraditional regimens. There remained a substantial increase in the cases of LOS in the nontraditional cohort (13.3% versus 3.1%, OR 4.789 $p=0.0084$).

A sub-analysis of the alternate antibiotic regimen demonstrated that there was no difference between the cephalosporin regimen and non-beta lactam regimens with similar rates of late onset sepsis in both cohorts (Table 2). Positive blood cultures were also more likely in the non-traditional regimen in the work-up for late onset sepsis (6.38 vs 1.27%, $p<0.05$). Composite neonatal morbidity was higher in the non-penicillin-based regimens, but this did not achieve statistical significance. Taken together, this data demonstrates that non-penicillin and azithromycin-based regimens with broader activity against Gram negative enteric bacteria and *E. coli* (M. Shaffer and C. Megli, submitted) are associated with increased rates of LOS.

Maternal Cephalosporin is associated with Reduced Mammary IgA

We next moved into a preclinical model to investigate the impact of perinatal antibiotics on infant health. To model antenatal antibiotic use, a variety of clinical-relevant dosages of antibiotics (including amoxicillin, ampicillin, cephalexin, metronidazole, and ceftazidime) were administered to pregnant dams via the drinking water for seven days: from embryonic day 14 until delivery. Mice were then placed on regular drinking water following delivery. On postnatal day 2 (PN2), IgA was significantly reduced in mammary glands following cephalexin and ceftazidime treatment, but not other penicillin-based antibiotics or metronidazole (Fig. 2A). This reduction was specific to the mammary glands, and neither cephalexin nor ceftazidime significantly decreased IgA in the serum (Fig. 2B). In the pups born to cephalexin or ceftazidime-treated dams, there was a significant decrease in intestinal IgA (Fig. 2C) but not serum IgA (Fig. 2D).

124 To understand the duration of decreased IgA in the mammary glands of dams and intestines of
125 nursing pups, we next assessed pups at PN7, and found decreased IgA in both the mammary
126 glands and neonatal intestinal tracts following prenatal cephalexin administration (Fig. 2D,E). In
127 contrast, there was no reduction of IgG in the dam or pups (Supplementary Fig. 1A,B). Thus,
128 maternal use of cephalexin and ceftazidime reduces the IgA in the mammary glands and
129 provided to the nursing pups, without limiting systemic IgA or IgG.

130 *Reduced mammary IgA is associated with increased E. coli colonization in mice.*

131 Though the cephalexin was administered to the dams exclusive to pregnancy, we observed a
132 noticeable shift in the microbiota of the pups, rather than the dams. Principal component analysis
133 revealed the microbiota of pups clustered distinctly from the dams, as expected given the age-
134 dependent development of the microbiota (Fig. 3A). However, microbiota from cephalexin-
135 treated dams did not separate distinctly from untreated dams, suggesting any effects on the
136 intestinal microbiota by cephalexin was transient (Supplementary Figure 2). Pups of cephalexin-
137 treated dams had the most observable microbial difference: an increase in *Enterobactericeae*
138 (Fig. 3B) and a significant increase in the relative abundance of *E. coli* (Fig. 3C), suggesting the
139 reduction in maternal IgA was associated with an increase in *E. coli* in the offspring. Antibiotic
140 treatment of pups or pregnant dams increased susceptibility to *Klebsiella pneumonia* in a model
141 of LOS, which was attributed to a reduction of *Lactobacillus* spp, including *Lactobacillus*
142 *murinis* in the intestinal microbiota of the pups (*8*). Decreased *Lactobacillus* was a strong
143 indicator of neonatal dysbiosis, and was associated with increased pathogen burden, suggesting
144 *lactobacillus* is associated with colonization resistance to enteric pathogens. Cephalexin
145 treatment of the dams did not reduce the abundance of *L. murinis* in the intestinal contents of the
146 dams or pups following cephalexin treatment (Fig. 3C), suggesting the expansion of *E. coli* is not
147 the result of reduced protection from *L. murinis.*

148 *Mammary IgA cross-reacts and binds to a variety of pathogenic E. coli.*

149 Maternal IgG has been shown to target enterotoxigenic *E. coli* in the neonatal intestine and
150 protect neonates from enteric infection (*7*), and we next sought to confirm maternal IgA can
151 cross-react with extraintestinal pathogenic *E. coli* species. Human IgA from donor human milk
152 was able to bind to a variety of *E. coli* strains (Fig. 4A), including both pathogenic and
153 commensal *E. coli* from neonates. We also observed IgG cross-reacted to *E. coli* strains, though

154 overall, there was less cross-reactive IgG compared to IgA. On average, donors had five times
155 more cross-reactive IgA than IgG (Fig. 4B). We observed significantly more binding of
156 pathogenic *E. coli* when compared to the lab strain K12 *E.coli*, suggesting maternal IgA may
157 have improved cross-reactivity to intestinal-derived *E. coli*. Certain samples had higher amounts
158 of crossreactivity to multiple *E. coli* isolates than others, which was independent of the total IgA
159 concentrations in the donor milk (Fig. 4C). IgA from the stomach contents of PN7 pups was able
160 to bind pathogenic *E. coli*, and this was decreased in PN7 pups from cephalexin treated dams
161 (Fig. 4D), interestingly, cross-reactivity of another bacterial pathogen, group B streptococcus
162 (GBS), remained unchanged after cephalexin treatment, suggesting an effect specific to *E. coli*-
163 targeting IgA. Additionally, we did not observe a decrease in IgA-bound bacteria in the stool of
164 pups following cephalexin treatment (Fig. 4E), suggesting a selective decrease in mammary IgA
165 able to bind specific taxa. Thus, maternal IgA can cross-react to a variety of *E. coli* and has the
166 potential to target *E. coli* and limit colonization in the nursing offspring.

167 *Reduced mammary IgA is associated with increased E. coli LOS in mice.*

168 It has been reported that the concentration of IgA in murine milk differs between murine strains,
169 potentially due to the difference in polyreactive IgA across strains, with BALB/c mice having
170 increased IgA compared to C57BL/6 mice (*37, 38*). Potentially due to this higher baseline of
171 mammary IgA, we did not observe a decrease in mammary IgA in BALB/c dams following
172 cephalexin treatment (Fig. 5A). Similarly, BALB/c pups from cephalexin-treated dams did not
173 have decreased intestinal IgA (Fig. 5B). When comparing strains, we observed a slight decrease
174 in IgA in the mammary glands and serum of C57BL/6 (mammary gland mean IgA 7.9 ug/ml),
175 without any reduction in IgG, when compared to BALB/c (mammary gland mean IgA 35 ug/ml),
176 similar to previous reports (compared Fig. 2B to Fig. 5A). This difference was more pronounced
177 in the pups, and C57BL/6 pups had significantly less IgA in the stomach and small intestine (6.2
178 ug/ml and 17.8 ug/ml) compared to BALB/c mice at postnatal day 5 (24.5 ug/ml, and 23.8
179 ug/ml), without any significant difference in serum IgA, or IgG (compare Fig. 2A to Fig. 5B).
180 Principal component analysis comparing the microbiota of the pups found the cephalexin
181 treatment had distinct effects on BALB/c pups as compared to B/6 pups (Supplementary Figure
182 2). Notably, in BALB/c pups, Gammaproteobacteria, and *E.coli* was not a major component of
183 the microbiota either with or without cephalexin (Fig. 5C). Thus, the increased *E. coli* in

184 C57BL/6 pups of cephalexin treated dams is associated with decreased mammary IgA, and
185 unlikely to be due to other off-target effects of cephalexin.

186 Minimal shifts in the microbial communities of control and cephalexin treatment C57BL/6 and
187 BALB/c dams was observed (Supplementary Figure 3), again suggesting cephalexin treatment
188 effects on the microbiota were transient, and restored by the time of lactation. We then compared
189 the microbial communities before (Day 0) and during cephalexin treatment (Day 4) and observed
190 the C57B/6 dams and BALB/c dams had different responses to the cephalexin treatment. While
191 both strains had decreased *Lactobacillus* strains, potentially a direct result of cephalexin in the
192 drinking water, there was an expansion of the *Bacteroidia*, particularly *Muribaculaceae* in the
193 C57Bl/6, while there was an expansion of the *Clostridia*, particularly *Lachnospiraceae*, in the
194 BALB/c. Interestingly, both strains had *Muribaculaceae* and *Lachnospiraceae* resident in the
195 intestinal microbiota prior to cephalexin, though at different abundances, so it remains unclear
196 why cephalexin treatment resulted in to disparate trajectories of the microbiota during antibiotic
197 administration.

198 To evaluate the functional role of decreased luminal IgA, PN5 pups were orally inoculated with
199 10^6 CFUs of BSI-B E. *coli*, a pathogenic ST131 *E.coli* isolated from the bloodstream of a
200 neonatal LOS patient. This strain of *E. coli* has been shown to translocate from the intestine
201 resulting in bacteremia in a model of neonatal sepsis (*17*). We observed increased mortality in
202 the pups from cephalexin treated C57BL/6 dams (Fig. 5D), recapitulating an increased risk to
203 LOS following cephalosporin use in our clinical cohort. There was no mortality seen in the pups
204 from cephalexin treated BALB/c dams. 48 hours following oral infection, there was a significant
205 increase in CFUs of *E. coli* in the stool of the infected pups from cephalexin treated C57BL/6
206 dams compared to the infected pups from untreated C57BL/6 dams or pups from BALB/c dams
207 (Fig. 5E). The increased risk of mortality was associated with presence of *E. coli* CFUs in the
208 spleen and mesenteric lymph node (MLN) at 48s hours post infection, though this was not
209 significantly different between treatments, potentially due to the low overall mortality (40%)
210 (Fig. 5F). Finally, we observed a significant difference by ANOVA in IgA in human milk
211 samples collected from mothers after antenatal treatment with non-traditional broad-spectrum
212 antibiotics, or traditional antibiotics for PPROM, as compared to no antibiotics. This suggests

213 maternal IgA may be disrupted by maternal antibiotics, however, our cohort did not have enough
214 cases to discern differences between individual antibiotics (Fig. 5G)

215 Taken together, we propose maternal IgA can limit intestinal colonization of *E.coli* in the nursing
216 offspring and decreased maternal IgA following broad spectrum prenatal antibiotics increases
217 risk of neonates to LOS. Our data have applications in clinical management as well as in
218 understanding the pathophysiology of late onset sepsis in neonates.

219

220 **Discussion**

221 PPROM is responsible for approximately 1/3 of all preterm birth and is a substantial risk factor
222 for complications associated with prematurity. The landmark Mercer trial on PPROM suggested
223 antibiotic management prolongs gestation and neonatal outcomes. However, there was a lack of
224 extensive neonatal follow up past discharge or transfer and sepsis was included in the primary
225 outcome only if it occurred <72 hours after delivery, also defined as early-onset sepsis (*39*). This
226 approach has been widely adopted in the United States and in our cohort patients universally
227 received antibiotics and achieved a substantially longer mean latency than was reported in the
228 initial RCT. Alternative antibiotics to the initial regimen have not been thoroughly studied with
229 the exception of the ORACLE trial that exchanged ampicillin for ampicillin/sulbactam and
230 amoxicillin for amoxicillin/sulbactam (*36*). In this trial the addition of beta-lactamases leads to
231 increased rates of adverse neonatal outcomes but additional studies on other antibiotic regimens
232 are not well studied.

233 The use of non-traditional antibiotics in the setting of PPROM is often secondary to a perceived
234 penicillin allergy. In a retrospective re-analysis of the MFMU BEAM trial, non-beta lactam
235 antibiotics were associated with increased rates of maternal endometritis and increased rates of
236 adverse neonatal outcomes but did not reach significance. Cephalosporins are currently
237 recommended for use with PPROM in the setting of a low-risk penicillin allergy, and therefore
238 our analysis is different in that we included cephalosporin use in the non-traditional antibiotic
239 cohort and saw increased rates of LOS. Taken together, these data suggest that more studies are
240 needed when using broader spectrum antibiotics in the absence of infection. Our data further

241 support the evidence in the ORACLE trial that broader spectrum antibiotics including those in
242 the beta-lactam class, can have adverse effects on neonates.

243 Our data is further supported by our preclinical model: antenatal cephalosporin was associated
244 with decreased maternal IgA in the mammary glands and gastrointestinal tract of the nursing
245 neonates. Decreased maternal IgA has been associated with increased *Enterobacteriaceae*
246 species that preceded necrotizing enterocolitis, another intestinally-related disease commonly
247 seen in preterm infants, showing the potent ability of maternal IgA in limiting potential enteric
248 pathogens in neonates (*40*). Here we show that in addition to protection from enteric disease by
249 limiting intestinal colonization, maternal IgA also protects against systemic dissemination
250 resulting in sepsis. This protection was strongly associated with maternal IgA and mammary IgA
251 cross-reacted to *E. coli* more than IgG, and we did not observe a decrease in maternal IgG in
252 mammary glands or the lumen of pups following cephalexin treatment.

253 Maternal IgA was associated with limiting both commensal *E. coli* as part of the microbiota, and
254 orally administered pathogenic *E. coli,* as both were expanded in B/6 pups following cephalexin
255 treatment. Prior observations have shown intestinal IgA can limit the growth of *E. coli*, and
256 selective IgA deficiency in humans resulted in increased *E. coli* (*41*). Maternal IgA responses
257 targeting *E. coli* have long been appreciated to be transferred to neonates in livestock mammals
258 (*22*) and orally administered monoclonal IgA protect against enteric bacterial infections,
259 including *E. coli* (*42*). *E. coli* colonization was not expanded in BALB/c mice, which had
260 significantly more IgA compared to B/6 pups. Nor did *E. coli* expand in BALB/c mice following
261 cephalexin treatment, explained by the lack of a decrease in IgA. There was no significant shift
262 in *E. coli* within the intestines of dams, either between murine strains or after antibiotics. Thus,
263 the expansion of *E. coli* in the pups is unlikely due to increased vertical transmission from the
264 dams.

265 The source of mammary derived IgA has been long connected to gut derived IgA responses in
266 the mother. IgA-committed lymphoblasts from the mesenteric lymph node home to the
267 mammary glands specifically during late pregnancy (*30*). These IgA responses can be induced
268 gut-associated lymphoid tissue, such as the Peyer's patches in response to specific bacteria,
269 including *Parabacteroides goldsteinii, B. acidifaciens,* and *Prevotella buccalis* (*31*). Disruption
270 of these bacterial species with vancomycin treatment during pregnancy and throughout lactation

reduced mammary IgA (*31*), however, we did not observe a significant shift in those species in our model. Indeed, the major microbial shift occurred during cephalexin treatment, when we observed different microbial trajectories in response to the antibiotics. In our model, cephalexin treatment, and the antibiotic-induced shift, is occurring during gestation between ED14-ED21. This could coincide with a time in life when IgA producing plasma cells are expanding or trafficking to the mammary gland in preparation for lactation. We only observed decreased maternal IgA with the cephalosporins: cephalexin and ceftazidime, and future work will focus on how these antibiotics are affecting the microbiota specifically during treatment and the larger affect this could have on mammary IgA production.

The basis for the specificity in IgA able to bind *E. coli* remains unclear. The decreased mammary IgA seemed to be directed to *E. coli*: we observed increased colonization of *E. coli*, and decreased binding of *E. coli*, following cephalexin treatment, and the decreased mammary IgA did not show a universal decrease in binding all bacteria. There was no decrease in cross-reactivity to GBS, and no decrease in overall IgA-bound bacteria in the stool. While dams contained *E. coli* within the intestinal microbiota at low abundance, they were not immunized against *E. coli* to induce a specific response. Similarly, the human IgA from donor milk had the ability to cross-react to multiple *E. coli* species. Thus, naturally induced IgA response can provide maternal protection. Naturally induced IgA have low-affinity but high cross-reactivity to a number of intestinal bacteria (*43*), and microbial exposure at the mucosal surfaces influence the B cell and IgA repertoire (*44*). Previous reports using auxotrophic *E. coli* suggest transient exposure to commensals can result in sustained IgA memory response in the absence of commensals (*28*). This IgA memory response can be disrupted following shifts to the microbiota (*28*). This has led to the speculation that IgA memory in response to commensals may be short-lived, with rapid turnover, and impaired expansion upon restimulation (*45*). However, *E. coli* in the dams was unchanged after cephalexin treatment, therefore it is unlikely antibiotic ablation of a specific species reduced IgA-producing plasma cells cross-reacting to that species. Further exploration into how this exposure can inform mammary IgA responses, and how disruptions to the maternal intestinal microbiota can disrupt mammary IgA responses remains should address this rapid crosstalk in the gut-mammary axis.

300 One limitation of our work is the limited translocation and mortality to *E. coli*, even following
301 cephalexin treatment. The slight increase in translocation of *E. coli* to the spleen and MLN
302 following cephalexin treatment potentially reflects the increased colonization in the lumen,
303 presenting the pathogen with increased opportunity to translocate. We have previously shown *E.*
304 *coli* translocation from the intestine was significantly increased when maternally supplied
305 epidermal growth factor and offspring expressed epidermal growth factor receptor was disrupted,
306 allowing for the formation of goblet-cell associated antigen passages, which allowed *E. coli* a
307 route across the epithelium (*9*). This suggests multiple maternal components may work in
308 tandem for the intestinal protection of neonate with IgA limiting pathogen colonization, and EGF
309 limiting access through goblet-cell associated antigen passages.

310 While we observed a trend toward decrease IgA in maternal milk following antibiotics, more
311 work is required to understand if there is a decrease in IgA following specific antibiotics, such as
312 cephalosporins. Additionally, measuring IgA in colostrum and throughout lactation, tracking
313 changes in the maternal microbiota, and assessing the binding reactivity of IgA following
314 antibiotics will allow us to understand how maternal IgA may be affected by maternal antibiotic
315 use. These data should be considered in light of reports advocating for treatment of intrauterine
316 infection using extended broad-spectrum antibiotics and expectant management, particularly in
317 the absence of culture data justifying the need for additional coverage. Our data reinforces what
318 was reported in the landmark ORACLE trial, that broader spectrum antibiotics may have
319 unanticipated neonatal consequences. Moreover, our data further suggest that the microbiome-
320 immune axis is relevant to neonatal health. Further studies in how antibiotics can cause a
321 perturbation of the microbiome-immune axis and lead to consequences in maternal-child health
322 are warranted.

323 In conclusion, selective maternal antibiotic treatment perinatally can result in decreased
324 mammary IgA that is important for limiting pathogen colonization and expansion in the
325 intestinal lumen of the nursing offspring. Our work builds on previous data showing the
326 contribution of maternal IgA in influencing the developing microbiota (*27*) and maternal
327 antibiotic use can decrease mammary IgA (*31*) by identifying a functional outcome of the
328 decreased mammary IgA in the nursing offspring. IgA binding of bacteria can create a positive
329 feedback loop the promote future IgA responses(*37, 38*), so disruption of this process may

330 reduce future IgA responses against potential enteric pathogens in the offspring. Future
331 directions should explore the gut-mammary axis to better understand how maternal antibiotics
332 affect mammary plasma cells.

333

334 **Methods**

335 *Patient inclusion*

336 Patients were identified using ICD9/ICD10 codes for PPROM and delivering within the UPMC
337 system between 2017-2020. Maternal and neonatal charts were reviewed, and multiple clinical
338 variables and outcomes were collected and deidentified. Data were reviewed by a maternal fetal
339 medicine specialist (CM) and a neonatologist (DB). Patients were excluded from analysis in the
340 setting of previable delivery less than 23 weeks, stillbirth, incomplete information regarding
341 antibiotic exposure and if they were not eligible for expectant management. Inclusion and
342 exclusion criteria are demonstrated in Figure 1. This study was approved through the University
343 of Pittsburgh IRB board.

344 *Definition of clinical outcomes*

345 Late onset sepsis was defined as diagnosis of sepsis greater than or equal to 7 days after delivery.
346 Necrotizing enterocolitis was included if radiologic findings were consistent with necrotizing
347 enterocolitis greater than 2A based on Bells Staging Criteria. Diagnosis of late onset sepsis and
348 spontaneous intestinal perforation were included if patients were clinically diagnosed and
349 treated. Neonates who underwent a diagnostic evaluation for late onset sepsis but did not
350 complete treatment were not considered to have late onset sepsis.

351 *Mice*

352 C57BL/6J and BALB/cJ mice were purchased from the Jackson Laboratory and bred in-house
353 at the Mayo Clinic. All mice were stored in standard housing. All mouse husbandry and
354 experiments involving mice were approved by the Mayo Clinic Institutional Animal Care and
355 Use Committee (IACUC).

356 *Bacterial Isolates*

357 E. coli strains BSI-A, BSI-B, BSI-C, BSI-D, BSI-E, and BSI-F are bloodstream isolates, along
358 with non-pathogenic strains C1 and C2, which were isolated from stool from infants. (*9*)
359 Commercial E. *coli* strain K12 (non-pathogenic) was purchased from the American Type Culture
360 Collection (Manassas, VA, USA). All bacteria were cultured at 37˚C in Lennox L (LB) Broth or
361 Agar (Invitrogen, Waltham, MA, USA). Bacterial strains were made nalidixic acid resistant as
362 previously described (*9*).

363 *E. Coli Infection*

364 Mice were orally gavaged with 50 uL of PBS containing 10^6 colony-forming units (CFUs) of
365 BSI-B on day of life five. Mice were weighed at 24hrs post infection to assess the impacts of the
366 infection. If mice had lost any weight at the 24hr check, they were euthanized and declared
367 moribund. All surviving mice were euthanized at 48hrs post-infection.

368 *Antibiotic Treatments*

369 14 days after mating (embryonic day 14), the male and female were separated. At this point,
370 antibiotics were given to the female pregnant mouse via drinking water until delivery. This
371 included amoxicillin (0.2mg/mL), ampicillin (0.4mg/mL), cephalexin (0.4mg/mL),
372 metronidazole (0.4mg/mL) or ceftazidime (0.4mg/mL). Mice were then placed on regular
373 drinking water following delivery of the litter.

374 *Quantification of Murine IgA/IgG or Human IgA*

375 Murine IgA and IgG were quantified using the IgA Mouse Uncoated ELISA Kit and the IgG
376 (Total) Mouse Uncoated ELISA Kit (Invitrogen). Samples were diluted in PBS, and assays were
377 performed according to manufacturer's instructions. The optical density was found using a
378 BioTek 800 TS absorbance reader at 450nm. Concentrations of IgA and IgA were reported as
379 ng/mL based on an intraassay standard curve. Human IgA was quantified from milk from
380 patients with PPROM and delivering within the UPMC system using the Total IgA was
381 quantified using Human IgA ELISA kit (Invitrogen). Concentrations of IgA and IgA were
382 reported as ng/mL based on an intraassay standard curve.

383 *16S Metagenomic Sequencing*

384 Stool from pups and dams were taken from uninfected mice on PN7. Dam stool was sequenced
385 per each individual dam, while stool from pups of the same litter were pooled for a
386 representative litter sequence. Murine stool DNA was isolated using the PowerFecal Pro DNA
387 Kit (QiAmp) and sequenced using the 16S Barcoding Kit 1-24 (SQK-16S024) on a GridION
388 (Nanopore). Sequences were aligned using centrifuge (*46, 47*). Data was analyzed using RStudio
389 software, and all mouse and human sequence data was removed during analysis. Data analysis
390 included alpha diversity, principal component analysis, and taxonomical distribution.

391 *Tissue Collection*

392 For DOL 5-7 pups, stool/colon contents were homogenized at 1mg/100uL PBS, stomach
393 contents in 200uL PBS, and small intestine in 100uL PBS, and serum was collected via cheek
394 puncture. For DOL 0-1 pups, colon, stomach, and small intestine homogenized in their entirety
395 in 100 uL PBS and serum was collected during euthanasia. For dam samples, stool was
396 homogenized at 1mg/mL PBS, and mammary glands at approximately 0.2729 g/840uL PBS. The
397 portion of mammary gland homogenized was slightly varied among samples, so all data is
398 normalized by weight.

399 *Tissue CFUs*

400 The spleen and mesenteric lymph node were homogenized in 300uL PBS, then serially diluted,
401 and plated for CFUs on LB plates. For stool plating, 0.1 mg of stool was homogenized in 300uL
402 PBS, then serially diluted, and plated for CFUs on LB plates. 20 ug/ml nalidixic acid was added
403 to MacConkey agar for selective growth of nalidixic acid resistant BSI *E coli*.

404 *Donor Milk*

405 Unpasteurized donor milk flagged for research use was obtained from the Minnesota Milk Bank
406 for Babies.

407 *Maternal Milk from Clinical Cohort*

408 For analysis of IgA from maternal milk following clinical antibiotic use, inclusion criteria for the
409 clinical cohort included premature infants born between 24-33 weeks of gestation born to
410 pregnant patients who were 18 or older with intent to breast feed their infants. Patients were
411 excluded if neonatal enteral feedings were contraindicated or if neonates were unable to pass

412 stool within 7 days. Maternal antibiotic exposure was performed through detailed chart review of
413 linked maternal charts by a maternal fetal medicine specialist (CM). Maternal patients with
414 antibiotics and without antibiotic administration were identified. Patients were excluded if they
415 received intrapartum antibiotics only (ie in the setting of GBS or surgical prophylaxis). Antenatal
416 antibiotic use were stratified into traditional antibiotics (azithromycin and ampicillin/amoxicillin)
417 used for PPROM, other antibiotic exposure (cephalosporin, gentamicin, clindamycin,
418 vancomycin combination use) or no antibiotics.

419 *Quantification of Donor Milk IgA*

420 Total IgA was quantified using Uncoated ELISA Kit (Invitrogen). Assay was performed in
421 triplicate. The optical density was found using a BioTek 800 TS absorbance reader at 450nm.
422 Concentrations of IgA were reported as ng/mL based on an intraassay standard curve (provided
423 by kit manufacturer).

424 Cross-reactive IgA was measured using the IgA Human Uncoated ELISA Kit (Invitrogen). For
425 the coating step, bacteria were grown up to 0.3 OD in LB Broth, spun down and resuspended in
426 PBS, then heat-killed (via heat block, for at least one hour) and added to the plate (100 uL a
427 well). The rest of the experimental protocol followed the manufacturer's instructions, data was
428 reported as the absorbance units.

429 *Statistical Analysis*

430 All statistical analysis was done using GraphPad Prism 6.0 (GraphPad Software Inc.). Data is
431 reported as mean +/- standard deviation. Differences between two groups was analyzed using
432 one-way ANOVAs, with Sidak's posttest. For the clinical cohort, continuous variables were
433 compared using students T test and dichotomous variables were compared using Chi-Squared
434 Analysis.

435 *Data availability:* Metagenomic 16S sequences will be deposited and available in the NIH
436 GenBank SRA database.

437 *Author Contributions:* KM, KG, KL, and JM performed antibiotic animal experiments, flow
438 cytometry, ELISAs, and data analysis. TH oversaw clinical cohort and milk collection. CM
439 oversaw clinical cohort design, data acquisition and analysis. DO and AS performed detailed

440 chart review of clinical cohort. KK performed 16S analysis. CM and KK wrote initial
441 manuscript, all authors discussed and edited the manuscript and contributed to figure preparation.
442
443
444
445

446 References:

447 1. M. A. AlQurashi, Survival rate of very low birth weight infants over a quarter century (1994-
448 2019): A single-institution experience. *J Neonatal Perinatal Med* **14**, 253-260 (2021).
449 2. Y. T. Jin, Y. Duan, X. K. Deng, J. Lin, Prevention of necrotizing enterocolitis in premature
450 infants - an updated review. *World J Clin Pediatr* **8**, 23-32 (2019).
451 3. F. Cortese *et al.*, Early and Late Infections in Newborns: Where Do We Stand? A Review.
452 *Pediatr Neonatol* **57**, 265-273 (2016).
453 4. A. Grishin, S. Papillon, B. Bell, J. Wang, H. R. Ford, The role of the intestinal microbiota in the
454 pathogenesis of necrotizing enterocolitis. *Semin Pediatr Surg* **22**, 69-75 (2013).
455 5. V. Mai *et al.*, Distortions in development of intestinal microbiota associated with late onset sepsis
456 in preterm infants. *PLoS One* **8**, e52876 (2013).
457 6. C. P. Hornik *et al.*, Early and late onset sepsis in very-low-birth-weight infants from a large group
458 of neonatal intensive care units. *Early human development* **88 Suppl 2**, S69-74 (2012).
459 7. W. Zheng *et al.*, Microbiota-targeted maternal antibodies protect neonates from enteric infection.
460 *Nature* **577**, 543-548 (2020).
461 8. J. R. Singer *et al.*, Preventing dysbiosis of the neonatal mouse intestinal microbiome protects
462 against late-onset sepsis. *Nature medicine* **25**, 1772-1782 (2019).
463 9. K. A. Knoop *et al.*, Maternal activation of the EGFR prevents translocation of gut-residing
464 pathogenic Escherichia coli in a model of late-onset neonatal sepsis. *Proceedings of*
465 *the National Academy of Sciences* **117**, 7941-7949 (2020).
466 10. B. K. Cole *et al.*, Route of infection alters virulence of neonatal septicemia Escherichia coli
467 clinical isolates. *PLoS ONE* **12**, e0189032 (2017).
468 11. M. A. Carl *et al.*, Sepsis from the gut: the enteric habitat of bacteria that cause late-onset neonatal
469 bloodstream infections. *Clin Infect Dis* **58**, 1211-1218 (2014).
470 12. M. A. Almuneef, R. S. Baltimore, P. A. Farrel, P. Reagan-Cirincione, L. M. Dembry, Molecular
471 typing demonstrating transmission of gram-negative rods in a neonatal intensive care unit in the
472 absence of a recognized epidemic. *Clin Infect Dis* **32**, 220-227 (2001).
473 13. P. L. Graham, 3rd, P. Della-Latta, F. Wu, J. Zhou, L. Saiman, The gastrointestinal tract serves as
474 the reservoir for Gram-negative pathogens in very low birth weight infants. *Pediatr Infect Dis J*
475 **26**, 1153-1156 (2007).
476 14. A. Smith *et al.*, Concordance of Gastrointestinal Tract Colonization and Subsequent Bloodstream
477 Infections With Gram-negative Bacilli in Very Low Birth Weight Infants in the Neonatal
478 Intensive Care Unit. *Pediatr Infect Dis J* **29**, 831-835 (2010).
479 15. S. Y. Kim, D. Y. Yi, Components of human breast milk: from macronutrient to microbiome and
480 microRNA. *Clin Exp Pediatr* **63**, 301-309 (2020).
481 16. C. G. Turin, T. J. Ochoa, The Role of Maternal Breast Milk in Preventing Infantile Diarrhea in
482 the Developing World. *Current tropical medicine reports* **1**, 97-105 (2014).
483 17. S. A. Kleist, K. A. Knoop, Understanding the Elements of Maternal Protection from Systemic
484 Bacterial Infections during Early Life. *Nutrients* **12**, (2020).
485 18. R. Bahl *et al.*, Infant feeding patterns and risks of death and hospitalization in the first half of
486 infancy: multicentre cohort study. *Bull World Health Organ* **83**, 418-426 (2005).
487 19. L. M. Lamberti, C. L. Fischer Walker, A. Noiman, C. Victora, R. E. Black, Breastfeeding and the
488 risk for diarrhea morbidity and mortality. *BMC Public Health* **11**, S15 (2011).
489 20. J. Cortez *et al.*, Maternal milk feedings reduce sepsis, necrotizing enterocolitis and improve
490 outcomes of premature infants. *Journal of Perinatology* **38**, 71-74 (2018).
491 21. R. N. Ashraf *et al.*, Breast feeding and protection against neonatal sepsis in a high risk
492 population. *Arch Dis Child* **66**, 488-490 (1991).

493 22. P. Porter, D. E. Noakes, W. D. Allen, Secretory IgA and antibodies to Escherichia coli in porcine
494 colostrum and milk and their significance in the alimentary tract of the young pig. *Immunology*
495 **18**, 245-257 (1970).
496 23. P. Van de Perre, Transfer of antibody via mother's milk. *Vaccine* **21**, 3374-3376 (2003).
497 24. J. N. Walterspiel, A. L. Morrow, M. L. Guerrero, G. M. Ruiz-Palacios, L. K. Pickering, Secretory
498 anti-Giardia lamblia antibodies in human milk: protective effect against diarrhea. *Pediatrics* **93**,
499 28-31 (1994).
500 25. J. R. Cruz, L. Gil, F. Cano, P. Caceres, G. Pareja, Breast milk anti-Escherichia coli heat-labile
501 toxin IgA antibodies protect against toxin-induced infantile diarrhea. *Acta Paediatr Scand* **77**,
502 658-662 (1988).
503 26. K. Sadeharju *et al.*, Maternal antibodies in breast milk protect the child from enterovirus
504 infections. *Pediatrics* **119**, 941-946 (2007).
505 27. E. W. Rogier *et al.*, Secretory antibodies in breast milk promote long-term intestinal homeostasis
506 by regulating the gut microbiota and host gene expression. *Proceedings of the National Academy*
507 *of Sciences* **111**, 3074-3079 (2014).
508 28. S. Hapfelmeier *et al.*, Reversible microbial colonization of germ-free mice reveals the dynamics
509 of IgA immune responses. *Science* **328**, 1705-1709 (2010).
510 29. J. Guo *et al.*, Role of IgA in the early-life establishment of the gut microbiota and immunity:
511 Implications for constructing a healthy start. *Gut microbes* **13**, 1-21 (2021).
512 30. M. E. Roux, M. McWilliams, J. M. Phillips-Quagliata, P. Weisz-Carrington, M. E. Lamm, Origin
513 of IgA-secreting plasma cells in the mammary gland. *The Journal of experimental medicine* **146**,
514 1311-1322 (1977).
515 31. K. Usami *et al.*, The gut microbiota induces Peyer's-patch-dependent secretion of maternal IgA
516 into milk. *Cell Reports* **36**, 109655 (2021).
517 32. J. M. Rodríguez, L. Fernández, V. Verhasselt, The Gut–Breast Axis: Programming Health for
518 Life. *Nutrients* **13**, (2021).
519 33. B. D. Reed, K. R. Schibler, H. Deshmukh, N. Ambalavanan, A. L. Morrow, The Impact of
520 Maternal Antibiotics on Neonatal Disease. *The Journal of pediatrics* **197**, 97-103.e103 (2018).
521 34. M. B. Azad *et al.*, Impact of maternal intrapartum antibiotics, method of birth and breastfeeding
522 on gut microbiota during the first year of life: a prospective cohort study. *BJOG* **123**, 983-993
523 (2016).
524 35. P. B. Bookstaver *et al.*, A Review of Antibiotic Use in Pregnancy. *Pharmacotherapy* **35**, 1052-
525 1062 (2015).
526 36. S. L. Kenyon, D. J. Taylor, W. Tarnow-Mordi, Broad-spectrum antibiotics for preterm, prelabour
527 rupture of fetal membranes: the ORACLE I randomised trial. *The Lancet* **357**, 979-988 (2001).
528 37. D. Ramanan *et al.*, An Immunologic Mode of Multigenerational Transmission Governs a Gut
529 Treg Setpoint. *Cell* **181**, 1276-1290.e1213 (2020).
530 38. F. Fransen *et al.*, BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which
531 Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity. *Immunity* **43**, 527-540
532 (2015).
533 39. B. M. Mercer *et al.*, Antibiotic Therapy for Reduction of Infant Morbidity After Preterm
534 Premature Rupture of the Membranes: A Randomized Controlled Trial. *JAMA* **278**, 989-995
535 (1997).
536 40. K. P. Gopalakrishna *et al.*, Maternal IgA protects against the development of necrotizing
537 enterocolitis in preterm infants. *Nature medicine* **25**, 1110-1115 (2019).
538 41. J. Fadlallah *et al.*, Microbial ecology perturbation in human IgA deficiency. *Science translational*
539 *medicine* **10**, eaan1217 (2018).
540 42. A. Richards, D. Baranova, N. J. Mantis, The prospect of orally administered monoclonal
541 secretory IgA (SIgA) antibodies to prevent enteric bacterial infections. *Human Vaccines &*
542 *Immunotherapeutics* **18**, 1964317 (2022).

543 43. J. J. Bunker *et al.*, Natural polyreactive IgA antibodies coat the intestinal microbiota. *Science* **358**,
544 eaan6619 (2017).
545 44. H. Li *et al.*, Mucosal or systemic microbiota exposures shape the B cell repertoire. *Nature* **584**,
546 274-278 (2020).
547 45. J. J. Bunker, A. Bendelac, IgA Responses to Microbiota. *Immunity* **49**, 211-224 (2018).
548 46. E. Whittle *et al.*, Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and
549 Antimicrobial Resistance in Patients at Risk of Surgical Site Infections. *mSphere* **7**, e0096421
550 (2022).
551 47. J. A. Yonkus *et al.*, "Answers in hours": A prospective clinical study using nanopore sequencing
552 for bile duct cultures. *Surgery* **171**, 693-702 (2022).

553

	Traditional n=320	Non-traditional n=49	OR (CI), p value
GA at PPROM	208.3	206	p=0.55
GA at delivery	217.0	215.4	p=0.65
No breast milk exposure	19 (6.1)	1 (2.2)	p=0.48
Neonatal death	13 (4.0)	4 (8.3)	2.168 (0.7422-6.902), p=0.18
EOS	15 (4.8)	1 (2.1)	.4348 (0.040-2.721),p=0.41
LOS	11 (3.5)	7 (14.9)	**4.836 (1.856-13.39), p=0.0008**
NEC≥2A	17 (5.4)	4 (8.5)	1.631 (.5716-4.715), p=0.39
LOS/NEC	27 (8.6)	9 (19.2)	**2.526 (1.057-5.599), p=0.02**
Composite outcome *	145 (44.9)	25 (52.1)	1.334 (0.7458-2.415) p=0.35

Table 1: Neonatal Outcomes following Antenatal Antibiotics

	Traditional (319)	Cephalosporin (20)	Non-beta lactam (28)
GA at PPROM	208.3	206.5	205.6
Latency days	8.7	11.9	7.8
GA at delivery	217.0	218.4	231.5
Neonatal death	13 (4)	1 (5)	3 (6.3)
Composite Neonatal Morbidity	145 (44.9)	11(55.0)	14(50.0)
EOS	15 (4.7)	0	1
LOS/SIP Culture positive	10 (3.2) 4	3 (15) 1	4 (14.8) 2
NEC (≥2A)	17 (5.1)	1 (5)	3 (11.1)
NEC<2A	6	2	0
LOS/NEC >2A	27 (8.6)	4 (20)	5 (18.5)
Other postnatal infection Pneumonia/Respiratory Diaper or Oral Candidiasis UTI Omphalitis/ cellulitis	15 (4.7) 4 3 6 2	1 (5.0) 0 1 0 0	2 (7.4) 0 0 1 1

Table 2: Subanalysis of traditional and nontraditional antibiotic regimens

Figure Legends

Figure 1: Clinical cohort schematic

Figure 2: Cephalosporins decrease mammary IgA and luminal IgA in nursing pups. Stated antibiotics were administered to pregnant dams in drinking water from ED 14 to delivery of litter, and tissue was analyzed on PND2. Total IgA was measured by ELISA from A) mammary glands of dams, B) serum of dams, C) colon contents of pups, and D) plasma of pups. Cephalexin was administered to pregnant dams in drinking water from ED 14 to delivery of litter, and tissue was analyzed on PND7. Total IgA was measured by ELISA from E) stomach contents (ST), small intestinal contents (SI), stool, and serum of pups, and F) stool, mammary and serum of dams. One way ANOVA was used to calculated statistical significance. N=3 dams and corresponding litters per group.

Figure 3: Cephalexin induced decrease mammary IgA is associated with increased E. coli colonization. A) Principal component analysis of 16s analysis of pups and dams indicate microbiota composition is based on phase of life (pups, blue vs dams, pink), and cephalexin (closed circles) had a more observable effect on pups compared to dams. B) Stacked bar plots of relative abundance of families in pup stool. C) Relative abundance of *E. coli* based on 16S analysis on stool of pups. D) Relative abundance of *Lactobacillus murinus* in dams and pups.

Figure 4: Human milk cross reacts to *E. coli* commensals and pathogens. A) Cross-reactive IgA from human donor milk was quantified against indicated *E. coli* isolates. B) Cross-reactive IgA from human donor milk was quantified against indicated *E. coli* isolates. C) Cross-reactive profiles for individual donor milk. D) Cross-reactive IgA from the stomach contents of pups following dam cephalexin treatment was measured against group B Streptococcus (GBS), and *E.*

coli. E) IgA+ bacteria from stool were measured by flow cytometry. N=20 donor milk specimens (A-C), N=3 independent litters per group (D). One-way ANOVA was used to calculate the statistical significance (A,B,D).

Figure 5: BALB/c. Cephalexin was administered to pregnant BALB/c dams in drinking water from ED 14 to ED21, tissue was analyzed on PND7. Total IgA (A) was measured by ELISA from stool, mammary glands, and serum of dams and (B) from stomach contents (ST), small intestinal contents (SI), stool, and serum of pups. C) Relative abundance of *E. coli* based on 16S analysis on stool of pups. 10^6 CFUs of pathogenic BSI-B *E. coli* were gavaged to BALB/c and C57BL/6 pups following cephalexin treatment of pregnant dams in drinking water from ED 14 to ED21. 10^6 CFUs of pathogenic BSI-B *E. coli* were gavaged to pups. D) Survival of pups following *E. coli* gavage on PN5. E) CFUs from stool were plated 48 hours following infection. F) CFUs from mesenteric lymph node (mLN) 48 hours following infection. G) Total IgA from human milk was quantified by ELISA. One way ANOVA was used to calculate statistical significance, A,B,C, E and F. Two way ANOVA was used to calculate statistical significance in G. Kaplan Meier Curve was used in D. N=3 dams and corresponding litters per group.


PPROM <34 weeks
n=517
Excluded
-Stillbirth
-Termination
-Comfort Measures
-No expectant management
-Absent details regarding antibiotics
-No follow up
-Known anomalies
Traditional Antibiotics
Ampicillin/Amoxicillin +Azithromycin
n=323
3 died in delivery room
8 died prior to 7 days
Non-Traditional Antibiotics
n=48
Non-Beta Lactam
n=28
1 died in delivery room
1 died prior to 7 days
Cephalosporin Regimen
n=20
0 deaths prior to 7 days


A
IgA in Dam Mammary Glands
Concentration ng/mL
15 000
10 000
5 000
0
*
*
Control
Amoxicillin
Ampicillin
Cephelexin
Metronidazole
Ceftazidime


B
IgA in Dam Serum
Concentration ng/mL
150 000
100 000
50 000
0
Control
Amoxicillin
Ampicillin
Cephelexin
Metronidazole
Ceftazidime


C
IgA in Pup Colons
Concentration ng/mL
15 000
10 000
5 000
0
*
*
Control
Amoxicillin
Ampicillin
Cephelexin
Metronidazole
Ceftazidime


D
IgA in Pup Plasma
Concentration ng/mL
800
600
400
200
0
Control
Amoxicillin
Ampicillin
Cephelexin
Metronidazole
Ceftazidime


E
IgA Concentration (ug/mL)
40
30
20
10
0
Control
Cephalexin
*
Stool
Mammary Gland
Serum


F
IgA concentration (ug/mL)
40
30
20
10
0
Control
Cephalexin
*
*
*
ST
SI
Stool
Serum


A
PC2
PC1
20
0
−20
−40
−25
0
25
50
Dam
Pup
Cephalexin
Control
B
Relative Abundance (%)
100
75
50
25
0
Control
Post Cephalexin
C
Relative Abundance % of E. coli
Control
Cephalexin
100
80
60
40
20
0
Dams
Pups
D
Relative Abundance (%) of L. murinus
Control
Cephalexin
100
80
60
40
20
0
Dams
Pups
Family
Lactobacillaceae
Enterobacteriaceae
Streptococcaceae
Staphylococcaceae
Bacillaceae
Yersiniaceae
Hafniaceae
Erwiniaceae
Vibrionaceae
Enterococcaceae
Families < 0.5% abundance


A
IgA A.U. per ml
100
10
1
0.1
*
BSI-A
BSI-B
BSI-C
BSI-E
BSI-F
C1
C2
K12
B
IgG A.U. per mL
100
10
1
0.1
*
BSI-A
BSI-B
BSI-C
BSI-F
C1
C2
C
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
BSI-A
BSI-B
BSI-C
BSI-E
BSI-F
C1
C2
K12
High (10-20)
Mid (5-10)
Low (1-5)
No (0-1)
D
Control
Cephalexin
IgA A.U per ml
15
10
5
0
*
GBS
E.coli
E
Control
Cephalexin
% IgA+ Fecal Bacteria
40
30
20
10
0
Pups
Dams


A
IgA concentration (ug/mL)
Control
Cephalexin
Stool
Mammary Gland
Serum
B
IgA concentration (ug/mL)
Control
Cephalexin
ST
SI
Stool
Serum
C
Relative Abundance (%) of E. coli
Dams
Pups
D
Survival (%)
Con BALB/c
Ceph BALB/c
Con C57BL/6
Ceph C57BL/6
Days Post Infection
E
E. coli CFUS/mL
Con
Ceph
Con
Ceph
BALB/c
C57BL/6
F
E. coli CFUs/mLN
Con
Ceph
Con
Ceph
BALB/c
C57BL/6
G
IgA ng/mL
No Antibiotics
Traditional Antibiotics
Non-Traditional Antibiotics